Elafibranor
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Elafibranor: From an Undetermined Original Indication to Amenorrhea (Disease)
One-Sentence Summary
Elafibranor (DrugBank DB05187) is a PPARα/δ dual agonist; formal records of its original approved indication are currently unavailable in this evidence pack. The TxGNN model predicts a possible association with Amenorrhea (disease), but this prediction is currently supported by 0 clinical trials and 0 publications — it is a model-only inference.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no approved indication data in source records |
| Predicted New Indication | Amenorrhea (disease) |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L5 |
| US Market Status | Not Marketed (Taiwan) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for elafibranor in this evidence pack, and its original approved indication is also not recorded. Based on the limited information available, elafibranor is characterized as a PPARα/δ dual agonist, a drug class primarily studied for its effects on lipid metabolism and insulin sensitivity.
The TxGNN model links elafibranor to amenorrhea purely through knowledge-graph embedding similarity (score 0.9986, rank 4210), not through any confirmed clinical or mechanistic pathway in this dataset. A theoretically plausible route exists — PPAR agonism can influence insulin sensitivity, which is relevant to PCOS-related menstrual irregularities — but this is speculative and is not corroborated by any clinical trial or literature evidence in the current pack.
Given the absence of both original-indication data and confirmatory studies, this prediction should be treated as an early-stage hypothesis generated by the model rather than an evidence-backed repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
Elafibranor is not currently marketed in Taiwan (market status: 未上市), and no license records are available.
Safety Considerations
Please refer to the package insert for safety information.
Note: A blocking data gap (DG001) was identified — TFDA label warnings/contraindications could not be retrieved, which prevents completion of the initial safety screening (S1) for this candidate.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests solely on TxGNN embedding similarity (L5, no clinical trials or literature), and a blocking safety data gap (missing TFDA label/contraindication data) prevents even an initial safety assessment. There is currently no basis to advance this candidate beyond hypothesis stage.
To proceed, the following is needed:
- TFDA (or originator) label data — warnings, contraindications, DDI (blocking gap DG001)
- Confirmed mechanism of action and original approved indication for elafibranor (gap DG002)
- Preclinical or mechanistic literature connecting PPARα/δ agonism to amenorrhea/menstrual disorders
- Any clinical trial or observational data specifically evaluating elafibranor in reproductive/endocrine indications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.